Therapy for Rare Cancers receives FDA approval following trials at Penn's Abramson Cancer
(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma. The approval was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania and was granted to Progenics Pharmaceuticals for AZEDRA (iobenguane I131). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 31, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves Drug for Rare Adrenal Tumors
(MedPage Today) -- Iobenguane I 131 active in pheochromocytoma, paraganglioma (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 30, 2018 Category: Primary Care Source Type: news

FDA Approves Azedra (iobenguane I 131) for Rare Adrenal Tumors
July 30, 2018 -- The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 30, 2018 Category: Drugs & Pharmacology Source Type: news

Pheochromocytoma/Paraganglioma and Cancer Metabolism Pheochromocytoma/Paraganglioma and Cancer Metabolism
A better understanding of the metabolic pathophysiology in pheochromocytomas/paragangliomas may lead to more targeted treatment for these tumors.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Pheochromocytoma: A Genetic and Diagnostic Update Pheochromocytoma: A Genetic and Diagnostic Update
Improved diagnostic tools offer earlier and more accurate detection of pheochromocytomas and paragangliomas.Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Penn-led trial shows AZEDRA can be effective, safe for treatment of rare neuroendocrine tumors
(University of Pennsylvania School of Medicine) A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2018 Category: Cancer & Oncology Source Type: news

Carvedilol Helps Protect Heart During PPGL Surgery
(MedPage Today) -- Med offers superior blocking for cardiac complications in pheochromocytoma (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 23, 2018 Category: Cardiology Source Type: news

Cabozantinib Promising in Malignant Adrenal Gland Tumors
(MedPage Today) -- Longer PFS in patients with pheochromocytomas, paragangliomas (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 21, 2018 Category: Endocrinology Source Type: news

Cabozantinib Looks Promising for Malignant Pheochromocytoma Cabozantinib Looks Promising for Malignant Pheochromocytoma
Tyrosine kinase inhibitor may offer several benefits to patients with malignant pheochromocytomas and paragangliomas, very rare forms of cancer that are difficult to treat.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

What Causes Flushing?
Discussion Flushing is usually thought of as a benign condition such as blushing, but can be quite irritating if it is frequent or persistent (i.e. menopausal hot flashes) or even pathologic (i.e. malignancy). “Flushing is a subjective and sensation of warmth that is accompanied by reddening of the skin anywhere on the body but favors the face, neck, and upper torso…. Flushing can be broadly divided into episodic or persistent. Episodic flashing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing result in a fixed facial erythema with telangiectasias and cyano...
Source: PediatricEducation.org - April 30, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Aspects of SDHA-Related Pheochromocytoma and Paraganglioma Aspects of SDHA-Related Pheochromocytoma and Paraganglioma
A better understanding of germline SDHA variants and mutations may allow for the earlier detection of paragangliomas.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Pheochromocytoma Surgery Pretreatments Both'Quite Good'Pheochromocytoma Surgery Pretreatments Both'Quite Good '
Phenoxybenzamine and doxazosin found equally effective in maintaining hemodynamic control during resection in PRESCRIPT trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 18, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Dec. 29, 2017 -- (Healthcare Sales & Marketing Network) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the... Biopharmaceuticals, Oncology, FDA Progenics Pharmaceuticals, AZEDRA, iobenguane, Pheochromocytoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 29, 2017 Category: Pharmaceuticals Source Type: news

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 29, 2017 Category: Drugs & Pharmacology Source Type: news

Progenics Pharmaceuticals Completes Submission of NDA for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it has completed the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 2, 2017 Category: Drugs & Pharmacology Source Type: news